Text Size

Allo BMT in Advanced Leukemia or High Grade Lymphoma

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186290
First received: September 13, 2005
Last updated: October 7, 2010
Last verified: October 2010
History of Changes

September 13, 2005
October 7, 2010
December 1989
October 2009   (final data collection date for primary outcome measure)
  • overall survival [ Time Frame: october 2009 ] [ Designated as safety issue: No ]
  • disease free survival [ Time Frame: October 2009 ] [ Designated as safety issue: No ]
  • - overall survival
  • - disease free survival
Complete list of historical versions of study NCT00186290 on ClinicalTrials.gov Archive Site
early and late toxicities of the treatment regimen [ Time Frame: October 2009 ] [ Designated as safety issue: Yes ]
early and late toxicities of the treatment regimen
Not Provided
Not Provided
 
Allo BMT in Advanced Leukemia or High Grade Lymphoma
Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Lymphoma, Non-Hodgkin
  • Leukemia
  • Blood and Marrow Transplant (BMT)
  • Lymphomas: Non-Hodgkin
Procedure: ablative allogeneic hematopoietic cell transplantation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
145
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:HLA identical donor

  • adequate organ function
  • other life threatening disease
Both
up to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00186290
BMT34, 74165, BMT34
Not Provided
Robert Lowsky, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Robert Lowsky Stanford University
Stanford University
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP